T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters

European Journal of Pharmacology

Volumn 443, Issue 1-3, 2002, Pages 179-184

  Inoue, Hirotaka ^a   Yano, Koji ^a   Noto, Tsunehisa ^a   Takagi, Michino ^a   Ikeo, Tomihiro ^a   Kikkawa, Kohei ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Cardiomyopathic hamster; Heart failure; Phosphodiesterase type 5; Survival

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE CARBOXYLATE SULFATE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HAMSTER; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEMODYNAMIC MONITORING; LONG TERM EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CARDIOMYOPATHIES; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; INJECTIONS, INTRAVENOUS; ISOQUINOLINES; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIDINES;

EID: 0037123870     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01598-4     Document Type: Article

References (32)

1. Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: Role of angiotensin II
2. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
3. Effect of vasodilator therapy on mortality in chronic congestive heart failure
4. Endothelial function in chronic congestive heart failure
5. Endothelial dysfunction in chronic heart failure. Experimental and clinical studies
6. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats
7. Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis
8. Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: Comparison with nitroprusside
9. Effects of vasodilators and perfusion pressure on coronary flow and simultaneous release of nitric oxide from guinea pig isolated hearts
10. Cardiomyopathic Syrian hamster: A possible model of human disease
11. Arrhythmogenic properties of the ventricular myocardium in cardiomyopathic Syrian hamster, BIO 14.6 strain
12. Effects of hydrochlorothiazide and captopril on the survival and heart weight of cardiomyopathic hamsters
13. Beta-blocker use in systolic heart failure and dilated cardiomyopathy
14. T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats
15. 2+ sensitizer, increases survival in cardiomyopathic hamsters
16. Endothelium-dependent vasodilation is attenuated in patients with heart failure
17. Impairment of endothelium dependent responses in a rat model of chronic heart failure: Effects of an exercise training protocol
18. Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent
19. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed
20. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension
21. Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters
22. Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats
23. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure
24. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure
25. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum
26. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide
27. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor
28. 1-Arylnaphthalene lignan: A novel scaffold for type 5 phosphodiesterase inhibitor
29. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
30. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function
31. Cardiovascular effects of T-1032, a novel and selective phosphodiesterase type V inhibitor, in normal and pulmonary hypertensive dogs
32. Clinical heart failure trials and the design rationale of Studies of Left Ventricular Dysfunction (SOLVD)